Cite
MLA Citation
Ana Oaknin et al.. “2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine.” International journal of gynecological cancer, vol. 32, n.d., pp. A251–A252. http://access.bl.uk/ark:/81055/vdc_100168340079.0x000037